Today: 1 July 2026
Browse Category

TSX:CRML 16 October 2025 - 26 January 2026

Critical Metals (CRML) Stock Explodes on Rare-Earth Boom – Gains Skyrocket Amid U.S. Investment Buzz

Critical Metals (CRML) Stock Explodes on Rare-Earth Boom – Gains Skyrocket Amid U.S. Investment Buzz

As of Oct.16, 2025 midday, CRML trades in the mid-$20s, rebounding from Oct.15’s close at $22.72 Marketbeat. That day’s 24% plunge followed a parabolic run higher: in early Oct the stock was only single digits, yet by Oct.13 it hit a 52-week high and by Oct.14 briefly traded near $32 ts2.tech. These gains made CRML one of the top Nasdaq performers. On Oct.6 alone the stock spiked over 60%, reflecting Reuters’s scoop on a possible U.S. equity investment Reuters ts2.tech. Volume has been enormous – Oct.15 saw ~51 million shares traded Stockinvest – and volatility remains very high. Technically, CRML broke well above long-term resistance in the $19–20 range during this rally Stockanalysis. Short-term moving averages are surging, prompting some buy signals Stockinvest. However, chart analysts warn that near-term support now lies around $17 ts2.tech, so a break below could see steep losses. Given the stock’s extreme run-up, many traders are taking profits or setting tight stop-loss orders to manage risk.
16 October 2025

Stock Market Today

  • Kymera Therapeutics (KYMR) up 51% YTD as atopic dermatitis drug hits milestones
    July 1, 2026, 2:57 PM EDT. Kymera Therapeutics (KYMR) is up nearly 51% this year, way ahead of the sector's 6.4%. The stock's gain is tied to progress on KT-621, an oral STAT6 degrader for atopic dermatitis and asthma. Kymera wrapped phase IIb enrollment in the BROADEN2 AD trial six months early, aiming to have the pivotal readout by late 2026. Earlier, phase Ib data showed strong STAT6 knockdown and safety. The FDA put KT-621 on Fast Track for moderate-to-severe AD and eosinophilic asthma. Separately, trials for KT-485, in partnership with Sanofi, led to a $20 million milestone, and Kymera is still developing KT-579. Its alliances with Sanofi and Gilead are part of the company's long-term plans.
Go toTop